Trial-Results center  
Clinical trial results database in 100 Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

heart failure - vasodilators therapy - all type of patient


Related trials

FUSION 2, 2008 - nesiritide vs placebo

FUSION 1, 2004 - nesiritide vs standard care

NICE (Lewis), 1999 - isosorbide dinitrate vs placebo

FIRST, 1997 - epoprostenol vs standard care

Ghose (vs captopril) , 1993 - vs captopril

Ghose (vs placebo), 1993 - vs placebo

V-HeFT II, 1991 - vs enalapril

VHeFT I (hydralazine ISDN), 1986 - hydralazine-ISDN vs placebo

VHeFT I (prazosin), 1986 - prazosin vs placebo

Magorien , 1984 - hydralazine vs placebo

Conradson , 1984 - hydralazine vs placebo

Higginbotham, 1983 - prazosin vs placebo

Markham, 1983 - prazosin vs placebo

Franciosa, 1982 - hydralazine vs placebo

Colucci, 1980 - prazosin vs placebo

Chatterjee, 1980 - hydralazine vs control

Franciosa , 1978 - isosorbide dinitrate vs placebo



See also:

  • All heart failure clinical trials
  • All clinical trials of vasodilators therapy
  • All clinical trials of
  •  

    V-HeFT II study, 1991

    download pdf: | vasodilators therapy for heart failure

    Treatments

    Studied treatment hydralazine 300mg ISDN 160mg daily
    Control treatment enalapril 20mg daily

    Patients

    Patients men with chronic congestive heart failure and cardiac dilatation (CT ratio>0.55) or LVEF <45% in association with reduced exercise tolerance

    Method and design

    Randomized effectives 401 / 403 (studied vs. control)
    Design Parallel groups
    Blinding double blind
    Follow-up duration 2.5y (range 0.5-5.7y)


    Results

    Endpoint Studied treat.
    n/N
    Control treat.
    n/N
    Graph RR [95% CI]

    cardiac death

    137 / 401
    112 / 403
    1,23 [1,00;1,51]

    All cause death

    153 / 401
    132 / 403
    1,16 [0,97;1,40]
    0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial
    Ref
    Studied treat. Control treat.
    cardiac death 137 / 401 (34,2%) 112 / 403 (27,8%) 1,23 [1,00;1,51]  
    All cause death 153 / 401 (38,2%) 132 / 403 (32,8%) 1,16 [0,97;1,40]  
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:

    Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    cardiac death 34,16% 27,79% 6,4%
    All cause death 38,15% 32,75% 5,4%

    Meta-analysis of all similar trials:

    vasodilators therapy in heart failure for all type of patient



    Reference(s)

    Trials register # NA
    Study web site link ,
    • Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.. N Engl J Med 1991;325:303-10
      Pubmed | Hubmed | Fulltext
    • Loeb HS, Johnson G, Henrick A, Smith R, Wilson J, Cremo R, Cohn JN. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group.. Circulation 1993;87:VI78-87
      Pubmed | Hubmed | Fulltext

    (c) 2004-2014 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend

    100100